PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 20591421-1 2010 Alpha-Galactosylceramide (alphaGalCer, KRN7000) has been identified as a modulator of immunological processes through its capacity to bind iNKT cells mediated by CD1d molecules. alpha-galactosylceramide 0-24 CD1d molecule Homo sapiens 162-166 20352088-7 2010 On stimulation with alpha-galactosylceramide loaded on human CD1d molecules, sooty mangabey NKT lymphocytes underwent degranulation and secreted IFN-gamma, TNF-alpha, IL-2, IL-13, and IL-10, indicating the presence of both effector and immunoregulatory functional capabilities. alpha-galactosylceramide 20-44 CD1d molecule Homo sapiens 61-65 20616071-1 2010 The glycolipid alpha-galactosylceramide (alpha-GalCer) has been shown to bind CD1d molecules to activate invariant natural killer T (iNKT) cells, and subsequently induce activation of various immune-competent cells, including dendritic cells, thereby providing a significant adjuvant effect for various vaccines. alpha-galactosylceramide 15-39 CD1d molecule Homo sapiens 78-82 20616071-1 2010 The glycolipid alpha-galactosylceramide (alpha-GalCer) has been shown to bind CD1d molecules to activate invariant natural killer T (iNKT) cells, and subsequently induce activation of various immune-competent cells, including dendritic cells, thereby providing a significant adjuvant effect for various vaccines. alpha-galactosylceramide 41-53 CD1d molecule Homo sapiens 78-82 19651460-7 2010 In contrast, addition of alpha-galactosylceramide (alpha-GC) induced expansion of Valpha24(+) iNKT cells as determined by using alpha-GC-loaded human CD1d dimers. alpha-galactosylceramide 25-49 CD1d molecule Homo sapiens 150-154 19651460-7 2010 In contrast, addition of alpha-galactosylceramide (alpha-GC) induced expansion of Valpha24(+) iNKT cells as determined by using alpha-GC-loaded human CD1d dimers. alpha-galactosylceramide 51-59 CD1d molecule Homo sapiens 150-154 19651460-7 2010 In contrast, addition of alpha-galactosylceramide (alpha-GC) induced expansion of Valpha24(+) iNKT cells as determined by using alpha-GC-loaded human CD1d dimers. alpha-galactosylceramide 128-136 CD1d molecule Homo sapiens 150-154 20173232-5 2010 Combined fluorescence and TREC imaging was applied to detect density, distribution and localization of YFP-labeled CD1d molecules on alpha-galactosylceramide (alphaGalCer)-loaded THP1 cells. alpha-galactosylceramide 133-157 CD1d molecule Homo sapiens 115-119 19879910-5 2010 iNKT cells were stained with 6B11 mAb, anti-TCRvalpha24 mAb, or alpha-galactosylceramide (GalCer)-loaded CD1d- tetramer and analyzed with flow-cytometric assays. alpha-galactosylceramide 64-88 CD1d molecule Homo sapiens 105-109 19879910-5 2010 iNKT cells were stained with 6B11 mAb, anti-TCRvalpha24 mAb, or alpha-galactosylceramide (GalCer)-loaded CD1d- tetramer and analyzed with flow-cytometric assays. alpha-galactosylceramide 90-96 CD1d molecule Homo sapiens 105-109 19620401-4 2009 ApoE dramatically enhances B-cell presentation of alpha-galactosylceramide (alphaGalCer), an exogenous CD1d presented antigen, inducing activation of NKT cells and the subsequent activation of B cells. alpha-galactosylceramide 50-74 CD1d molecule Homo sapiens 103-107 19590406-5 2009 We measured cytokines from NKT cells after stimulation with either alpha-galactosyl ceramide-loaded CD1d dimers (DimerX-alphaGalCer) or phorbol myristate acetate and ionomycin. alpha-galactosylceramide 67-92 CD1d molecule Homo sapiens 100-104 18378792-2 2008 Using the structure of the human semiinvariant NKT TCR-CD1d-alpha-galactosylceramide (alpha-GalCer) complex as a guide, we undertook an alanine scanning mutagenesis approach to define the energetic basis of this interaction between the NKT TCR and CD1d. alpha-galactosylceramide 60-84 CD1d molecule Homo sapiens 55-59 19592275-0 2009 Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors. alpha-galactosylceramide 33-58 CD1d molecule Homo sapiens 28-32 19506241-1 2009 Short or polyunsaturated lipid variants of the NKT cell antigen alpha-galactosylceramide (alphaGC) exhibit decreased potency and a Th2 bias in vivo despite conserved TCR contact residues and stable binding to CD1d at neutral and acidic pH. alpha-galactosylceramide 64-88 CD1d molecule Homo sapiens 209-213 19414797-2 2009 alpha-Galactosylceramide (alpha-GalCer) is presented by CD1d molecule on APCs to invariant Valpha14(+) NKT (iNKT) cells, which upon activation rapidly produce large amounts of immunomodulatory cytokines, leading to activation of a variety of innate and adaptive immune cells. alpha-galactosylceramide 0-24 CD1d molecule Homo sapiens 56-69 19479838-5 2009 Only 7 and 24 associated with plate-bound recombinant CD1d prevented stimulation of iNKT cells by alpha-galactosylceramide (alpha-GalCer). alpha-galactosylceramide 98-122 CD1d molecule Homo sapiens 54-58 19479849-5 2009 Triazoles 14 and 15 prevent binding of alpha-galactosylceramide (alpha-GalCer) to plate-bound human CD1d and subsequent T-cell response to alpha-GalCer. alpha-galactosylceramide 39-63 CD1d molecule Homo sapiens 100-104 19479849-5 2009 Triazoles 14 and 15 prevent binding of alpha-galactosylceramide (alpha-GalCer) to plate-bound human CD1d and subsequent T-cell response to alpha-GalCer. alpha-galactosylceramide 65-77 CD1d molecule Homo sapiens 100-104 19047090-9 2008 Ascites treatment also partially blocked the ability of alpha-galactosylceramide-loaded CD1d-immunoglobulin-based aAPC to activate NKT cells. alpha-galactosylceramide 56-80 CD1d molecule Homo sapiens 88-92 19369232-2 2009 iNKT cells are activated through their T-cell receptors by glycolipid moieties (typically the alpha-galactosylceramide [alpha-GalCer] derivative KRN7000) presented within CD1d. alpha-galactosylceramide 94-118 CD1d molecule Homo sapiens 171-175 18712867-3 2008 An alpha-galactosyl ceramide (alpha-GalCer) bearing a carbamate group at the 6"-OH position was tethered to the surface, and the dissociation constant on surface with CD1d was determined to reflect the multivalent interaction. alpha-galactosylceramide 3-28 CD1d molecule Homo sapiens 167-171 18378792-2 2008 Using the structure of the human semiinvariant NKT TCR-CD1d-alpha-galactosylceramide (alpha-GalCer) complex as a guide, we undertook an alanine scanning mutagenesis approach to define the energetic basis of this interaction between the NKT TCR and CD1d. alpha-galactosylceramide 86-98 CD1d molecule Homo sapiens 55-59 18378792-2 2008 Using the structure of the human semiinvariant NKT TCR-CD1d-alpha-galactosylceramide (alpha-GalCer) complex as a guide, we undertook an alanine scanning mutagenesis approach to define the energetic basis of this interaction between the NKT TCR and CD1d. alpha-galactosylceramide 86-98 CD1d molecule Homo sapiens 248-252 18202973-1 2008 BACKGROUND: NKT cells recognize glycolipids presented by CD1d on antigen-presenting cells (APC) and have been largely characterized by their ability to be activated by alpha-galactosylceramide, a glycolipid not expressed on mammalian cells. alpha-galactosylceramide 168-192 CD1d molecule Homo sapiens 57-61 17690880-1 2008 BACKGROUND: Human Valpha24 natural killer T (NKT) cells are activated by the specific ligand, alpha-galactosylceramide (alpha-GalCer), in a CD1d-dependent manner. alpha-galactosylceramide 94-118 CD1d molecule Homo sapiens 140-144 18253930-0 2008 Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules. alpha-galactosylceramide 79-103 CD1d molecule Homo sapiens 144-148 18068183-1 2008 The alpha-galactosylceramide (alphaGalCer)-loaded CD1d tetramer remains the most powerful tool in identifying natural killer T (NKT) cells, a subpopulation of T cells that express an unusual semi-invariant T cell antigen receptor, and mediate a variety of proinflammatory and immunoregulatory functions. alpha-galactosylceramide 4-28 CD1d molecule Homo sapiens 50-54 17362268-1 2007 CD1d-restricted invariant natural killer T (iNK T) cells activated by their experimental ligand alpha-galactosylceramide (alpha-GC) can produce both T helper 1 (Th1) and Th2 cytokines and display regulatory functions. alpha-galactosylceramide 96-120 CD1d molecule Homo sapiens 0-4 18024119-1 2007 The invariant (i) natural killer (NK)T cells consistently express the Valpha14 chain of the T cell receptor (TCR) and recognize alpha-galactosylceramide (alpha-GalCer) presented by the nonpolymorphic presentation molecule CD1d. alpha-galactosylceramide 128-152 CD1d molecule Homo sapiens 222-226 17581592-4 2007 Here we describe the structure of a human NKT TCR in complex with CD1d bound to the potent NKT-cell agonist alpha-galactosylceramide, the archetypal CD1d-restricted glycolipid. alpha-galactosylceramide 108-132 CD1d molecule Homo sapiens 66-70 17581592-4 2007 Here we describe the structure of a human NKT TCR in complex with CD1d bound to the potent NKT-cell agonist alpha-galactosylceramide, the archetypal CD1d-restricted glycolipid. alpha-galactosylceramide 108-132 CD1d molecule Homo sapiens 149-153 17363727-2 2007 CD4 is also expressed by invariant natural killer T cells (iNKT), which recognize natural and synthetic lipid antigens, such as alpha-galactosyl ceramide (alpha-GalCer), in association with the MHC class I-like CD1d molecule. alpha-galactosylceramide 128-153 CD1d molecule Homo sapiens 211-224 17599630-0 2007 Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. BACKGROUND/AIMS: The glycosphingolipid alpha-galactosylceramide has been shown to activate invariant natural killer T cells when presented in the context of CD1d and induces powerful antiviral immune responses via the production of inflammatory cytokines. alpha-galactosylceramide 50-74 CD1d molecule Homo sapiens 274-278 17599630-0 2007 Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. BACKGROUND/AIMS: The glycosphingolipid alpha-galactosylceramide has been shown to activate invariant natural killer T cells when presented in the context of CD1d and induces powerful antiviral immune responses via the production of inflammatory cytokines. alpha-galactosylceramide 156-180 CD1d molecule Homo sapiens 274-278 17362268-1 2007 CD1d-restricted invariant natural killer T (iNK T) cells activated by their experimental ligand alpha-galactosylceramide (alpha-GC) can produce both T helper 1 (Th1) and Th2 cytokines and display regulatory functions. alpha-galactosylceramide 122-130 CD1d molecule Homo sapiens 0-4 17510531-3 2007 Initial characterizations revealed that both cell lines expressed an invariant T cell antigen receptor, which could be readily detected with alpha-galactosylceramide-loaded CD1d : Ig fusion protein (alpha-GalCer/CD1d). alpha-galactosylceramide 141-165 CD1d molecule Homo sapiens 173-177 17510531-3 2007 Initial characterizations revealed that both cell lines expressed an invariant T cell antigen receptor, which could be readily detected with alpha-galactosylceramide-loaded CD1d : Ig fusion protein (alpha-GalCer/CD1d). alpha-galactosylceramide 141-165 CD1d molecule Homo sapiens 212-216 17312118-3 2007 We found that dendritic cells (DCs) potentiated iNKT cells to respond to a minimal amount of ligand alpha-galactosylceramide (alphaGalCer) through CD1d-dependent autoreactive responses that require endosomal processing and CD1d trafficking. alpha-galactosylceramide 100-124 CD1d molecule Homo sapiens 147-151 17312126-3 2007 We show that IL-21 on its own enhances survival of NKT cells in vitro, and IL-21 increases the proliferation of NKT cells in combination with IL-2 or IL-15, and particularly with the CD1d-restricted glycosphingolipid Ag alpha-galactosylceramide. alpha-galactosylceramide 220-244 CD1d molecule Homo sapiens 183-187 17372201-8 2007 Saposin B was also the most efficient in mediating alpha-galactosylceramide binding to recombinant plate-bound CD1d and facilitating NKT cell activation. alpha-galactosylceramide 51-75 CD1d molecule Homo sapiens 111-115 17014832-1 2006 alpha-Galactosyl-ceramide (1) has been identified as a powerful modulator of immunological processes through its capacity to bind CD1d molecules and specifically activate invariant natural killer (NK)-like T cells (iNKT cells). alpha-galactosylceramide 0-25 CD1d molecule Homo sapiens 130-134 18989404-9 2007 The generation of tetramers of alpha Galactosyl ceramide (a-Galcer) with CD1d has significant insight into the biology of NKT cells. alpha-galactosylceramide 31-56 CD1d molecule Homo sapiens 73-77 17277112-3 2007 Hepatic (alpha-galactosyl-ceramide-loaded CD1d dimer binding) NKT cells produce predominantly IL-4 when stimulated with glycolipid-presenting HC but predominantly IFN-gamma when stimulated with glycolipid-presenting dendritic cells. alpha-galactosylceramide 9-34 CD1d molecule Homo sapiens 42-46 16914507-1 2006 CD1d-restricted NKT cells are activated by TCR-mediated stimulation via CD1d plus lipid antigens such as alpha-galactosylceramide (alpha-GalCer). alpha-galactosylceramide 105-129 CD1d molecule Homo sapiens 0-4 17028247-1 2006 PURPOSE: Human Valpha24 natural killer T (Valpha24 NKT) cells bearing an invariant Valpha24JalphaQ antigen receptor are activated by a glicolipid ligand alpha-galactosylceramide (alphaGalCer; KRN7000) in a CD1d-dependent manner. alpha-galactosylceramide 153-177 CD1d molecule Homo sapiens 206-210 17015708-4 2006 Schwann cells activated iNKT cells in a CD1d-dependent manner in the presence of alpha-galactosylceramide. alpha-galactosylceramide 81-105 CD1d molecule Homo sapiens 40-44 17015708-5 2006 Surprisingly, the cytokine production of iNKT cells stimulated by alpha-galactosylceramide presented by CD1d+ Schwann cells showed a predominance of Th2-associated cytokines such as IL-5 and IL-13 with a marked deficiency of proinflammatory Th1 cytokines such as IFN-gamma or TNF-alpha. alpha-galactosylceramide 66-90 CD1d molecule Homo sapiens 104-108 16323834-1 2005 [structures: see text] The phytosphingosine-containing alpha-galactosylceramides (alpha-GalCers), KRN7000 and OCH, have been shown to activate NKT cells via interaction with CD1d, a member of the CD1 family of antigen presenting proteins. alpha-galactosylceramide 55-80 CD1d molecule Homo sapiens 174-178 16647712-1 2006 CD1d presentation of alpha-galactosyl ceramides to natural killer T cells has been a focal point of the study of regulatory T cells. alpha-galactosylceramide 21-47 CD1d molecule Homo sapiens 0-4 16380959-1 2006 Human Valpha24(+)Vbeta11(+) NKT cells are a unique T cell population specifically and potently activated by alpha-galactosylceramide (alphaGalCer; KRN7000) presented by CD1d. alpha-galactosylceramide 108-132 CD1d molecule Homo sapiens 169-173 16373666-6 2006 CD1d-expressing HSCs display short- and long-term clonogenic potential and can present the glycolipid alpha-galactosylceramide to iNKT cells. alpha-galactosylceramide 102-126 CD1d molecule Homo sapiens 0-4 16505600-3 2006 iNKT cells recognize glycolipid antigens such as alpha-galactosylceramide (alpha-GC) presented by CD1d, non-pormorphic MHC class I-like molecule, and rapidly secrete large amounts of cytokines including IL-4 and IFN-gamma upon activation. alpha-galactosylceramide 49-73 CD1d molecule Homo sapiens 98-102 16505600-3 2006 iNKT cells recognize glycolipid antigens such as alpha-galactosylceramide (alpha-GC) presented by CD1d, non-pormorphic MHC class I-like molecule, and rapidly secrete large amounts of cytokines including IL-4 and IFN-gamma upon activation. alpha-galactosylceramide 75-83 CD1d molecule Homo sapiens 98-102 16301636-4 2005 In the absence of the endogenous mouse CD1d (mCD1d), the expression of hCD1d on thymocytes, but not on APCs, was sufficient to select Valpha14i NKT cells that proved functional when activated ex vivo with the Ag alpha-galactosyl ceramide. alpha-galactosylceramide 212-237 CD1d molecule Homo sapiens 71-76 16177088-7 2005 From normal and diabetic PLN, one-third of CD1d tetramer+-sorted T cell clones were reactive with CD1d transfectants or proliferated/secreted cytokine in response to alpha-galactosylceramide-pulsed PBMCs; tetramer-staining T cell clones from diabetic PLN did not secrete IL-4. alpha-galactosylceramide 166-190 CD1d molecule Homo sapiens 43-47 16210612-5 2005 Using MLR assays we demonstrate that in the presence of the CD1d-presented glycolipid alpha-galactosylceramide (alphaGC) alloreactivity is enhanced (37 +/- 12%; p < 0.001) in an iNKT cell-dependent manner. alpha-galactosylceramide 86-110 CD1d molecule Homo sapiens 60-64 16025562-1 2005 Human Valpha24+ Vbeta11+ natural killer T cells (NKT cells) are "natural memory" T cells that detect glycolipid antigens such as alpha-galactosylceramide (alpha-GalCer) presented on CD1d. alpha-galactosylceramide 129-153 CD1d molecule Homo sapiens 182-186 16007090-0 2005 The crystal structure of human CD1d with and without alpha-galactosylceramide. alpha-galactosylceramide 53-77 CD1d molecule Homo sapiens 31-35 16007090-1 2005 The glycolipid alpha-galactosylceramide binds with high affinity to CD1d and stimulates natural killer T cells. alpha-galactosylceramide 15-39 CD1d molecule Homo sapiens 68-72 16007090-2 2005 Here we report the crystal structure of human CD1d in complex with synthetic alpha-galactosylceramide at a resolution of 3.0 A. alpha-galactosylceramide 77-101 CD1d molecule Homo sapiens 46-50 16007091-2 2005 Here we report the crystal structure of CD1d in complex with a short-chain synthetic variant of alpha-galactosylceramide at a resolution of 2.2 A. alpha-galactosylceramide 96-120 CD1d molecule Homo sapiens 40-44 15744356-8 2005 CD1d+ leukemic blasts were able to present alpha-GalCer via CD1d to cytotoxic CD1d-restricted T cells, which induced apoptosis of ALL cells that was inhibited by mAb to CD1d. alpha-galactosylceramide 43-55 CD1d molecule Homo sapiens 0-4 15814694-1 2005 Va14Ja18 natural T (iNKT) cells are innate, immunoregulatory lymphocytes that recognize CD1d-restricted lipid Ags such as alpha-galactosylceramide (alpha GalCer). alpha-galactosylceramide 122-146 CD1d molecule Homo sapiens 88-92 15778340-5 2005 Interestingly, in this context, macrophage participation in the CD1d Ag presentation of alpha-galactosylceramide to NK T cells is not necessary. alpha-galactosylceramide 88-112 CD1d molecule Homo sapiens 64-68 15744356-8 2005 CD1d+ leukemic blasts were able to present alpha-GalCer via CD1d to cytotoxic CD1d-restricted T cells, which induced apoptosis of ALL cells that was inhibited by mAb to CD1d. alpha-galactosylceramide 43-55 CD1d molecule Homo sapiens 60-64 15744356-8 2005 CD1d+ leukemic blasts were able to present alpha-GalCer via CD1d to cytotoxic CD1d-restricted T cells, which induced apoptosis of ALL cells that was inhibited by mAb to CD1d. alpha-galactosylceramide 43-55 CD1d molecule Homo sapiens 60-64 15744356-8 2005 CD1d+ leukemic blasts were able to present alpha-GalCer via CD1d to cytotoxic CD1d-restricted T cells, which induced apoptosis of ALL cells that was inhibited by mAb to CD1d. alpha-galactosylceramide 43-55 CD1d molecule Homo sapiens 60-64 15722411-0 2005 Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. alpha-galactosylceramide 77-102 CD1d molecule Homo sapiens 14-18 15722411-1 2005 A form of alpha-galactosylceramide, KRN7000, activates CD1d-restricted Valpha14-invariant (Valpha14i) natural killer (NK) T cells and initiates multiple downstream immune reactions. alpha-galactosylceramide 10-34 CD1d molecule Homo sapiens 55-59 15639652-1 2005 CD1d-restricted natural killer T (NKT) cells are involved in the regulation of various immune responses, and have been shown to inhibit viral replication in animal hepatitis models when activated by the glycolipid alpha-galactosylceramide (alpha-GalCer, KRN7000). alpha-galactosylceramide 214-238 CD1d molecule Homo sapiens 0-4 15187105-10 2004 Incubation of target cells with the ligands for CD1d, alpha-galactosylceramide (alpha-GalCer), and beta-GalCer abolishes the protective effect of CD1d in our in vitro killing assays. alpha-galactosylceramide 54-78 CD1d molecule Homo sapiens 146-150 16178273-4 2005 Moreover, in the same patients we studied the intrahepatic and peripheral NKT cell recognition of alpha-galactosyl ceramide antigen in the context of CD1d. alpha-galactosylceramide 98-123 CD1d molecule Homo sapiens 150-154 16178273-7 2005 In patients with viral hepatitis, the intrahepatic CD1d expression parallels the recruitment of CD56+Valpha24Vbeta11+ NKT cells in the liver which recognize CD1d presenting glycolipids such as alpha-galactosyl ceramide, suggesting that the intrahepatic T cell immunity may focus on glycolipid antigens. alpha-galactosylceramide 193-218 CD1d molecule Homo sapiens 51-55 16178273-7 2005 In patients with viral hepatitis, the intrahepatic CD1d expression parallels the recruitment of CD56+Valpha24Vbeta11+ NKT cells in the liver which recognize CD1d presenting glycolipids such as alpha-galactosyl ceramide, suggesting that the intrahepatic T cell immunity may focus on glycolipid antigens. alpha-galactosylceramide 193-218 CD1d molecule Homo sapiens 157-161 15493902-2 2004 An alpha-galactosylceramide containing relatively long lipid chains has been the subject of intense study because, when presented by CD1d to natural killer T cells, it stimulates the release of both proinflammatory and immunomodulatory cytokines. alpha-galactosylceramide 3-27 CD1d molecule Homo sapiens 133-137 15599405-1 2004 Activation of invariant CD1d-dependent NK T cells (iNKT cells) in vivo through administration of the glycolipid ligand alpha-galactosylceramide (alpha-GalCer) or the sphingosine-truncated alpha-GalCer analog OCH leads to CD40 signaling as well as the release of soluble molecules including type 1 and gamma interferons that contribute to DC maturation. alpha-galactosylceramide 119-143 CD1d molecule Homo sapiens 24-28 15304644-2 2004 They react to the glycolipid alpha-galactosyl ceramide (alpha-GalCer) presented by CD1d, and they may have important regulatory functions. alpha-galactosylceramide 29-54 CD1d molecule Homo sapiens 83-87 15304644-2 2004 They react to the glycolipid alpha-galactosyl ceramide (alpha-GalCer) presented by CD1d, and they may have important regulatory functions. alpha-galactosylceramide 56-68 CD1d molecule Homo sapiens 83-87 15187105-10 2004 Incubation of target cells with the ligands for CD1d, alpha-galactosylceramide (alpha-GalCer), and beta-GalCer abolishes the protective effect of CD1d in our in vitro killing assays. alpha-galactosylceramide 80-92 CD1d molecule Homo sapiens 146-150 14512316-1 2004 Human Valpha24+Vbeta11+ natural killer T (NKT) cells are a distinct CD1d-restricted lymphoid subset specifically and potently activated by alpha-galactosylceramide (alpha-GalCer) (KRN7000) presented by CD1d on antigen-presenting cells. alpha-galactosylceramide 139-163 CD1d molecule Homo sapiens 68-72 14961579-0 2004 CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. alpha-galactosylceramide 71-95 CD1d molecule Homo sapiens 0-4 14961579-3 2004 The synthetic lipid alpha-galactosylceramide (alpha-GalCer) has been characterized as a potent stimulator of CD1d-restricted T cells. alpha-galactosylceramide 20-44 CD1d molecule Homo sapiens 109-113 15185366-9 2004 The loading was dose dependent and could be inhibited by an established CD1d ligand, alpha-galactosylceramide. alpha-galactosylceramide 85-109 CD1d molecule Homo sapiens 72-76 14716312-4 2004 Here we show that saposins, although not required for the autoreactive recognition of CD1d by natural killer T cells, are indispensable for the binding of an exogenous lipid antigen, alpha-galactosylceramide, to CD1d in the endocytic pathway. alpha-galactosylceramide 183-207 CD1d molecule Homo sapiens 212-216 14512316-1 2004 Human Valpha24+Vbeta11+ natural killer T (NKT) cells are a distinct CD1d-restricted lymphoid subset specifically and potently activated by alpha-galactosylceramide (alpha-GalCer) (KRN7000) presented by CD1d on antigen-presenting cells. alpha-galactosylceramide 139-163 CD1d molecule Homo sapiens 202-206 14512316-1 2004 Human Valpha24+Vbeta11+ natural killer T (NKT) cells are a distinct CD1d-restricted lymphoid subset specifically and potently activated by alpha-galactosylceramide (alpha-GalCer) (KRN7000) presented by CD1d on antigen-presenting cells. alpha-galactosylceramide 165-177 CD1d molecule Homo sapiens 68-72 14512316-1 2004 Human Valpha24+Vbeta11+ natural killer T (NKT) cells are a distinct CD1d-restricted lymphoid subset specifically and potently activated by alpha-galactosylceramide (alpha-GalCer) (KRN7000) presented by CD1d on antigen-presenting cells. alpha-galactosylceramide 165-177 CD1d molecule Homo sapiens 202-206 12764370-1 2003 Natural killer T (NKT) cells with an invariant T-cell receptor for alpha-galactosylceramide (alphaGalCer) that is presented by CD1d have been reported to be cytotoxic for myelomonocytic leukemia cells. alpha-galactosylceramide 67-91 CD1d molecule Homo sapiens 127-131 12764370-1 2003 Natural killer T (NKT) cells with an invariant T-cell receptor for alpha-galactosylceramide (alphaGalCer) that is presented by CD1d have been reported to be cytotoxic for myelomonocytic leukemia cells. alpha-galactosylceramide 93-104 CD1d molecule Homo sapiens 127-131 11264173-1 2001 Human Valpha24NKT cells are activated by alpha-galactosylceramide (alpha-GalCer)-pulsed dendritic cells in a CD1d-dependent and a T-cell receptor-mediated manner. alpha-galactosylceramide 41-65 CD1d molecule Homo sapiens 109-113 12803920-3 2003 Fluorescent tetrameric complexes made from soluble recombinant CD1d/alpha-galactosylceramide complexes allowed highly sensitive and specific ex vivo and in vitro detection and functional characterization of novel human T-lymphocyte populations. alpha-galactosylceramide 68-92 CD1d molecule Homo sapiens 63-67 12730881-4 2003 RESULTS: MODE-K and freshly isolated human IECs exhibited dose-dependent, CD1d-restricted presentation of the functional glycolipid antigen, alpha-galactosylceramide (alpha GalCer), to the mouse NK-T cell hybridoma, DN32.D3. alpha-galactosylceramide 141-165 CD1d molecule Homo sapiens 74-78 12505720-1 2003 Human CD1d-restricted natural killer T (NKT) cells, which are postulated to regulate the immune response in several clinical settings, can be activated by alpha-galactosylceramide (alpha-GalCer) presented by CD1d molecules on antigen presenting cells (APCs). alpha-galactosylceramide 155-179 CD1d molecule Homo sapiens 6-10 12505720-1 2003 Human CD1d-restricted natural killer T (NKT) cells, which are postulated to regulate the immune response in several clinical settings, can be activated by alpha-galactosylceramide (alpha-GalCer) presented by CD1d molecules on antigen presenting cells (APCs). alpha-galactosylceramide 155-179 CD1d molecule Homo sapiens 208-212 12023346-0 2002 Valpha24-JalphaQ-independent, CD1d-restricted recognition of alpha-galactosylceramide by human CD4(+) and CD8alphabeta(+) T lymphocytes. alpha-galactosylceramide 61-85 CD1d molecule Homo sapiens 30-34 12023346-1 2002 Human CD1d molecules present an unknown ligand, mimicked by the synthetic glycosphingolipid alpha-galactosylceramide (alphaGC), to a highly conserved NKT cell subset expressing an invariant TCR Valpha24-JalphaQ paired with Vbeta11 chain (Valpha24(+)Vbeta11(+) invariant NK T cell (NKT(inv))). alpha-galactosylceramide 92-116 CD1d molecule Homo sapiens 6-10 11869900-2 2002 The recent development of fluorescent CD1d tetramers loaded with the synthetic glycolipid alpha-galactosyl-ceramide has led to a clearer definition of NKT-cell subsets as well as important insights into their developmental origin. alpha-galactosylceramide 90-115 CD1d molecule Homo sapiens 38-42 11830474-1 2002 The antimetastatic effect of the CD1d-binding glycolipid, alpha-galactosylceramide (alpha-GalCer), is mediated by NK1.1(+)T (NKT) cells; however, the mechanisms behind this process are poorly defined. alpha-galactosylceramide 58-82 CD1d molecule Homo sapiens 33-37 11830474-1 2002 The antimetastatic effect of the CD1d-binding glycolipid, alpha-galactosylceramide (alpha-GalCer), is mediated by NK1.1(+)T (NKT) cells; however, the mechanisms behind this process are poorly defined. alpha-galactosylceramide 84-96 CD1d molecule Homo sapiens 33-37 11714786-2 2001 However, it has been difficult to demonstrate self ligand specificity in this system, as most Valpha14+ T cells do not exhibit significant autoreactivity despite high reactivity to alpha-galactosylceramide presented by CD1d (alpha-GalCer/CD1d). alpha-galactosylceramide 181-205 CD1d molecule Homo sapiens 219-223 11714786-2 2001 However, it has been difficult to demonstrate self ligand specificity in this system, as most Valpha14+ T cells do not exhibit significant autoreactivity despite high reactivity to alpha-galactosylceramide presented by CD1d (alpha-GalCer/CD1d). alpha-galactosylceramide 181-205 CD1d molecule Homo sapiens 238-242 11564825-3 2001 Invariant NK T cells were markedly decreased in peripheral blood from advanced prostate cancer patients, and their ex vivo expansion with a CD1d-presented lipid Ag (alpha-galactosylceramide) was diminished compared with healthy donors. alpha-galactosylceramide 165-189 CD1d molecule Homo sapiens 140-144 12707346-0 2003 The paradox of immune molecular recognition of alpha-galactosylceramide: low affinity, low specificity for CD1d, high affinity for alpha beta TCRs. alpha-galactosylceramide 47-71 CD1d molecule Homo sapiens 107-111 12594262-12 2003 NKT cells, which home preferentially to the liver and respond to the CD1d-restricted ligand alpha-galactosylceramide (alpha-GalCer). alpha-galactosylceramide 92-116 CD1d molecule Homo sapiens 69-73 12890950-3 2003 They are CD1d-dependent and can be stimulated by alpha-galactosylceramide. alpha-galactosylceramide 49-73 CD1d molecule Homo sapiens 9-13 12360465-3 2002 METHODS: We used a human CD1d (hCD1d) tetramer produced by a baculovirus expressing recombinant CD1d protein complexed with alpha-galactosylceramide (alpha-GalCer) and quantitated hCD1d tetramer reactive cells in blood and liver from controls and patients with primary biliary cirrhosis (PBC). alpha-galactosylceramide 124-148 CD1d molecule Homo sapiens 25-29 12360465-3 2002 METHODS: We used a human CD1d (hCD1d) tetramer produced by a baculovirus expressing recombinant CD1d protein complexed with alpha-galactosylceramide (alpha-GalCer) and quantitated hCD1d tetramer reactive cells in blood and liver from controls and patients with primary biliary cirrhosis (PBC). alpha-galactosylceramide 124-148 CD1d molecule Homo sapiens 31-36 12360465-3 2002 METHODS: We used a human CD1d (hCD1d) tetramer produced by a baculovirus expressing recombinant CD1d protein complexed with alpha-galactosylceramide (alpha-GalCer) and quantitated hCD1d tetramer reactive cells in blood and liver from controls and patients with primary biliary cirrhosis (PBC). alpha-galactosylceramide 124-148 CD1d molecule Homo sapiens 32-36 12213347-5 2002 The recent generation of tetramers of alpha-galactosyl ceramide (alpha-GalCer) with CD1d has already permitted significant insight into the biology of NKT cells. alpha-galactosylceramide 38-63 CD1d molecule Homo sapiens 84-88 12213347-5 2002 The recent generation of tetramers of alpha-galactosyl ceramide (alpha-GalCer) with CD1d has already permitted significant insight into the biology of NKT cells. alpha-galactosylceramide 65-77 CD1d molecule Homo sapiens 84-88 11264173-1 2001 Human Valpha24NKT cells are activated by alpha-galactosylceramide (alpha-GalCer)-pulsed dendritic cells in a CD1d-dependent and a T-cell receptor-mediated manner. alpha-galactosylceramide 67-79 CD1d molecule Homo sapiens 109-113 11164462-9 2000 Another subset of T cells that expresses the NK receptors is the alpha-galactosyl-ceramide specific T cell subset defined by the expression of canonical Valpha24JalphaQ TCR, recognition of CD1d and secretion of high amounts of IL-4 and IFN-gamma. alpha-galactosylceramide 65-90 CD1d molecule Homo sapiens 189-193 10360961-1 1999 Murine NKT cells can recognize alpha-galactosylceramide (alpha-GalCer) in the context of a class Ib CD1d molecule. alpha-galactosylceramide 31-55 CD1d molecule Homo sapiens 100-113 11145860-3 2000 They recognize a glycolipid antigen (alpha -galactosylceramide) or parasitic glycophosphatidylinositols (GPI) in association with a monomorphic class Ib, CD1d, and perform various functions such as Th1 and Th2 cytokine production as well as perforin/granzyme B-mediated cytotoxicity. alpha-galactosylceramide 37-62 CD1d molecule Homo sapiens 154-158 10884613-2 2000 Group II CD1 or CD1d molecules are recognized by the specialized NK T-cell subset, and this reactivity can be greatly augmented by alpha-galactosylceramide, a glycosphingolipid derived from a marine sponge. alpha-galactosylceramide 131-155 CD1d molecule Homo sapiens 16-20 10779745-1 2000 Human V alpha 24+ NKT cells with an invariant TCR (V alpha 24-J alpha Q) have been shown to be specifically activated by synthetic glycolipids such as alpha-galactosylceramide and alpha-glucosylceramide in a CD1d-restricted and V alpha 24 TCR-mediated manner. alpha-galactosylceramide 151-175 CD1d molecule Homo sapiens 208-212 10822576-1 1999 [formula: see text] A representative alpha-galactosylceramide (alpha-GalCer), KRN7000, can activate NKT cells through CD1d molecules, which play an essential role in the generation of the strong antitumor activity of KRN7000. alpha-galactosylceramide 37-61 CD1d molecule Homo sapiens 118-122 10450506-3 1999 Murine and human CD1d molecules can present glycolipid antigens such as alpha-galactosylceramide (alpha-GalCer) to CD1d-restricted natural killer (NK) T cells. alpha-galactosylceramide 72-96 CD1d molecule Homo sapiens 17-21 10450506-3 1999 Murine and human CD1d molecules can present glycolipid antigens such as alpha-galactosylceramide (alpha-GalCer) to CD1d-restricted natural killer (NK) T cells. alpha-galactosylceramide 72-96 CD1d molecule Homo sapiens 115-119 10450506-3 1999 Murine and human CD1d molecules can present glycolipid antigens such as alpha-galactosylceramide (alpha-GalCer) to CD1d-restricted natural killer (NK) T cells. alpha-galactosylceramide 98-110 CD1d molecule Homo sapiens 17-21 10450506-3 1999 Murine and human CD1d molecules can present glycolipid antigens such as alpha-galactosylceramide (alpha-GalCer) to CD1d-restricted natural killer (NK) T cells. alpha-galactosylceramide 98-110 CD1d molecule Homo sapiens 115-119 10360961-1 1999 Murine NKT cells can recognize alpha-galactosylceramide (alpha-GalCer) in the context of a class Ib CD1d molecule. alpha-galactosylceramide 57-69 CD1d molecule Homo sapiens 100-113 33499253-6 2021 Interestingly, when stimulated only via CD1d+ dendritic cells (DCs) loaded with alpha-galactosylceramide (alpha-GalCer), both CD38- and BCMA-CAR iNKT cells expanded well, without losing their CAR- or TCR-dependent cytotoxic activities. alpha-galactosylceramide 80-104 CD1d molecule Homo sapiens 40-44 9782129-0 1998 CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. alpha-galactosylceramide 32-56 CD1d molecule Homo sapiens 0-4 34953481-3 2021 Invariant Natural Killer T (iNKT) cells are a subpopulation of T lymphocytes, activated by recognition of glycolipid ligands such as alpha-Galactosylceramide presented by CD1d, produce and secrete several cytokines, including IFN-gamma and IL-4. alpha-galactosylceramide 133-157 CD1d molecule Homo sapiens 171-175 34936686-10 2021 IL-15 enhanced CD69, CD1d and CD11a expression on alpha-Galcer treated iNKT cells; 7. alpha-galactosylceramide 50-62 CD1d molecule Homo sapiens 21-25 34706265-3 2021 The most common stimulant is the glycolipid alpha-Galactosyl Ceramide (alpha-GalCer), which stimulates iNKT cells when presented by CD1d, an MHC class I-like molecule expressed by antigen-presenting cells (APC). alpha-galactosylceramide 44-69 CD1d molecule Homo sapiens 132-136 34706265-3 2021 The most common stimulant is the glycolipid alpha-Galactosyl Ceramide (alpha-GalCer), which stimulates iNKT cells when presented by CD1d, an MHC class I-like molecule expressed by antigen-presenting cells (APC). alpha-galactosylceramide 71-83 CD1d molecule Homo sapiens 132-136 34706265-4 2021 Another stimulant used is alpha-GalCer-loaded DimerX, a CD1d-Ig fusion protein which stimulates iNKT cells in an APC-independent fashion. alpha-galactosylceramide 26-38 CD1d molecule Homo sapiens 56-60 34524668-2 2021 They recognize lipid antigens presented by CD1d molecules and can be specifically activated by alpha-galactosylceramide (alpha-GalCer) in vitro. alpha-galactosylceramide 95-119 CD1d molecule Homo sapiens 43-47 34524668-2 2021 They recognize lipid antigens presented by CD1d molecules and can be specifically activated by alpha-galactosylceramide (alpha-GalCer) in vitro. alpha-galactosylceramide 121-133 CD1d molecule Homo sapiens 43-47 34524672-4 2021 Importantly, recombinant CD1d fusion proteins loaded with alpha-GalCer demonstrated sustained activation of iNKT cells upon repeated injections and superior tumor control, as compared to alpha-GalCer treatment. alpha-galactosylceramide 58-70 CD1d molecule Homo sapiens 25-29 33942544-2 2021 alpha-Galactosylceramide (alpha-GC) is a synthetic glycolipid that is recognized by the invariant T-cell receptor of invariant natural killer T (iNKT) cells in a CD1d-restricted manner. alpha-galactosylceramide 0-24 CD1d molecule Homo sapiens 162-166 33942544-2 2021 alpha-Galactosylceramide (alpha-GC) is a synthetic glycolipid that is recognized by the invariant T-cell receptor of invariant natural killer T (iNKT) cells in a CD1d-restricted manner. alpha-galactosylceramide 26-34 CD1d molecule Homo sapiens 162-166 33499253-6 2021 Interestingly, when stimulated only via CD1d+ dendritic cells (DCs) loaded with alpha-galactosylceramide (alpha-GalCer), both CD38- and BCMA-CAR iNKT cells expanded well, without losing their CAR- or TCR-dependent cytotoxic activities. alpha-galactosylceramide 106-118 CD1d molecule Homo sapiens 40-44 31982233-1 2020 alpha-Galactosylceramide (alpha-GalCer) is recognized by the CD1d proteins on antigen-presenting cells at the ceramide moiety and the galactose moiety is presented to iNKT cells, which stimulates the immune responses. alpha-galactosylceramide 0-24 CD1d molecule Homo sapiens 61-65 33361143-7 2021 Several molecules with the capacity to bind to CD1d have been discovered, including alpha-galactosylceramide. alpha-galactosylceramide 84-108 CD1d molecule Homo sapiens 47-51 33193386-1 2020 Murine and human invariant natural killer T (iNKT) lymphocytes are activated by alpha-galactosylceramide (alpha-GalCer) presented on CD1d. alpha-galactosylceramide 80-104 CD1d molecule Homo sapiens 133-137 33193386-1 2020 Murine and human invariant natural killer T (iNKT) lymphocytes are activated by alpha-galactosylceramide (alpha-GalCer) presented on CD1d. alpha-galactosylceramide 106-118 CD1d molecule Homo sapiens 133-137 32714765-0 2020 A Designed alpha-GalCer Analog Promotes Considerable Th1 Cytokine Response by Activating the CD1d-iNKT Axis and CD11b-Positive Monocytes/Macrophages. alpha-galactosylceramide 11-23 CD1d molecule Homo sapiens 93-97 31190065-5 2020 METHODS: In a cross-sectional study of 101 HIV-infected and -uninfected South African patients with active TB and controls, iNKT cells were enumerated using alpha-galactosylceramide-loaded CD1d tetramers and subsequently functionally characterised by flow cytometry. alpha-galactosylceramide 157-181 CD1d molecule Homo sapiens 189-193 30783507-2 2019 In this Letter, we designed and synthesized a novel series of CD1d ligand alpha-galactosylceramides (alpha-GalCers) in which the acyl chain backbone of the lipid was incorporated with fluorine atoms. alpha-galactosylceramide 74-99 CD1d molecule Homo sapiens 62-66 31544285-1 2020 alpha-Galactosylceramide (alpha-GalCer; KRN7000) is a ligand for the glycoprotein CD1d that presents lipid antigens to natural killer T cells. alpha-galactosylceramide 0-24 CD1d molecule Homo sapiens 82-86 31544285-1 2020 alpha-Galactosylceramide (alpha-GalCer; KRN7000) is a ligand for the glycoprotein CD1d that presents lipid antigens to natural killer T cells. alpha-galactosylceramide 26-38 CD1d molecule Homo sapiens 82-86 31615552-5 2019 Their proliferative capacity and cytokine production were investigated following activation with CD1d ligand alpha-galactosylceramide (alpha-GalCer). alpha-galactosylceramide 109-133 CD1d molecule Homo sapiens 97-101 31141185-3 2019 Type I NKT cells, most extensively studied, are identified by a semi-invariant Valpha14-Jalpha18 (mouse, Valpha24-Jalpha18 in humans) TCR reactive to the prototypic ligand alpha-galactosylceramide presented on CD1d. alpha-galactosylceramide 172-196 CD1d molecule Homo sapiens 210-214 31316500-8 2019 Analogous to human iNKT cells, in vitro stimulation of porcine leukocytes with the CD1d ligand alpha-galactosylceramide resulted in rapid iNKT cell proliferation, evidenced by an increase in frequency and Ki-67 expression. alpha-galactosylceramide 95-119 CD1d molecule Homo sapiens 83-87 31748533-3 2019 Here we describe a population of type II NKT cells that recognise and respond to the microbial antigen, alpha-glucuronosyl-diacylglycerol (alpha-GlcADAG) presented by CD1d, but not the prototypical type I NKT cell agonist, alpha-galactosylceramide. alpha-galactosylceramide 223-247 CD1d molecule Homo sapiens 167-171 31649670-0 2019 Structure-Function Implications of the Ability of Monoclonal Antibodies Against alpha-Galactosylceramide-CD1d Complex to Recognize beta-Mannosylceramide Presentation by CD1d. alpha-galactosylceramide 80-104 CD1d molecule Homo sapiens 105-109 31649670-0 2019 Structure-Function Implications of the Ability of Monoclonal Antibodies Against alpha-Galactosylceramide-CD1d Complex to Recognize beta-Mannosylceramide Presentation by CD1d. alpha-galactosylceramide 80-104 CD1d molecule Homo sapiens 169-173 30858151-6 2019 Once loaded with the iNKT cell lipid agonist alpha-galactosyl ceramide (alphaGC), the CD1d-CD19 fusion induces robust in vitro activation of and cytokine production by human iNKT cells. alpha-galactosylceramide 45-70 CD1d molecule Homo sapiens 86-90 30783507-2 2019 In this Letter, we designed and synthesized a novel series of CD1d ligand alpha-galactosylceramides (alpha-GalCers) in which the acyl chain backbone of the lipid was incorporated with fluorine atoms. alpha-galactosylceramide 101-114 CD1d molecule Homo sapiens 62-66 30322965-6 2018 moDCs but not moLCs produced inflammatory cytokines after stimulation with CD1b and CD1d ligands mycolic acid and alpha-galactosylceramide, respectively. alpha-galactosylceramide 114-138 CD1d molecule Homo sapiens 84-88 30519237-0 2018 Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: alpha-Galactosylceramide and Beyond. alpha-galactosylceramide 78-102 CD1d molecule Homo sapiens 13-17 30051730-5 2018 iNKT cells have potent in vivo and in vitro anti-tumor activities against CD1d-positve gastric cancer in the presence of alpha-galactosylceramide. alpha-galactosylceramide 121-145 CD1d molecule Homo sapiens 74-78 30245690-1 2018 Invariant natural killer T (iNKT) cells produce copious amounts of cytokines in response to T-cell receptor (TCR) stimulation by recognizing antigens such as alpha-galactosylceramide (alpha-GalCer) presented on CD1d; thus, orchestrating other immune cells to fight against pathogen infection and tumors. alpha-galactosylceramide 158-182 CD1d molecule Homo sapiens 211-215 30013569-0 2018 CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: alpha-Galactosylceramide and Beyond. alpha-galactosylceramide 65-89 CD1d molecule Homo sapiens 0-4 29163493-3 2017 Systemic treatments with the CD1d-antitumor fusion proteins loaded with the agonist alpha-galactosylceramide (alphaGalCer) led to specific iNKT cell activation, resulting in a sustained growth inhibition of established tumors expressing HER2 or CEA, while treatment with the free alphaGalCer was ineffective. alpha-galactosylceramide 84-108 CD1d molecule Homo sapiens 29-33 29904582-3 2018 We and others have found a glycolipid, called alpha-galactosylceramide (alpha-GalCer), which could be presented on CD1d expressed by antigen-presenting cells (APCs) and stimulate natural killer T (NKT) cells. alpha-galactosylceramide 46-70 CD1d molecule Homo sapiens 115-119 29904582-3 2018 We and others have found a glycolipid, called alpha-galactosylceramide (alpha-GalCer), which could be presented on CD1d expressed by antigen-presenting cells (APCs) and stimulate natural killer T (NKT) cells. alpha-galactosylceramide 72-84 CD1d molecule Homo sapiens 115-119 28633979-8 2017 The alpha-galactosylceramide, a ligand for CD1d, showed increased CD1d expression as well as cell proliferation which was opposite to the effects of ZER. alpha-galactosylceramide 4-28 CD1d molecule Homo sapiens 43-47 28633979-8 2017 The alpha-galactosylceramide, a ligand for CD1d, showed increased CD1d expression as well as cell proliferation which was opposite to the effects of ZER. alpha-galactosylceramide 4-28 CD1d molecule Homo sapiens 66-70 26107189-1 2015 Alpha-galactosylceramide (GC), a lipid antigen present on CD1d molecules, is a unique adjuvant that enables a strong antitumor effect to be induced via activation of natural killer T cells. alpha-galactosylceramide 0-24 CD1d molecule Homo sapiens 58-62 28655912-1 2017 Invariant Natural Killer T-cells (iNKT-cells) are an attractive target for immune response modulation, as upon CD1d-mediated stimulation with KRN7000, a synthetic alpha-galactosylceramide, they produce a vast amount of cytokines. alpha-galactosylceramide 163-187 CD1d molecule Homo sapiens 111-115 27648599-4 2016 A series of the ligands, alpha-galactosyl ceramide (alpha-GalCer) derivatives containing polar groups in the acyl chain, was synthesized, and the structure-activity relationship studies demonstrated that simple modification from a methylene to an amide group in the long fatty acyl chain, when introduced at optimal positions, enhanced the CD1d recognition of the glycolipid ligands. alpha-galactosylceramide 25-50 CD1d molecule Homo sapiens 340-344 27648599-4 2016 A series of the ligands, alpha-galactosyl ceramide (alpha-GalCer) derivatives containing polar groups in the acyl chain, was synthesized, and the structure-activity relationship studies demonstrated that simple modification from a methylene to an amide group in the long fatty acyl chain, when introduced at optimal positions, enhanced the CD1d recognition of the glycolipid ligands. alpha-galactosylceramide 52-64 CD1d molecule Homo sapiens 340-344 26875526-3 2016 We describe an atypical population of CD1d-alpha-galactosylceramide (alpha-GalCer)-reactive human NKT cells that differ markedly from the prototypical TRAV10-TRAJ18-TRBV25-1(+) type I NKT cell repertoire. alpha-galactosylceramide 43-67 CD1d molecule Homo sapiens 38-42 26875526-3 2016 We describe an atypical population of CD1d-alpha-galactosylceramide (alpha-GalCer)-reactive human NKT cells that differ markedly from the prototypical TRAV10-TRAJ18-TRBV25-1(+) type I NKT cell repertoire. alpha-galactosylceramide 69-81 CD1d molecule Homo sapiens 38-42 26481266-1 2015 Conventional dendritic cells (cDCs) present alpha-galactosylceramide (alphaGC) to invariant natural killer T (iNKT) cells through CD1d. alpha-galactosylceramide 44-68 CD1d molecule Homo sapiens 130-134 28717498-4 2015 We present here the synthesis and analysis of vaccines based on conjugation of MHC-binding peptide epitopes to alpha-galactosylceramide, a glycolipid presented by the nonpolymorphic antigen-presenting molecule CD1d to provoke the stimulatory activity of type I natural killer T (NKT) cells. alpha-galactosylceramide 111-135 CD1d molecule Homo sapiens 210-214 26107189-1 2015 Alpha-galactosylceramide (GC), a lipid antigen present on CD1d molecules, is a unique adjuvant that enables a strong antitumor effect to be induced via activation of natural killer T cells. alpha-galactosylceramide 26-28 CD1d molecule Homo sapiens 58-62 24076636-3 2013 We describe a population of human Vdelta1(+) gammadelta T cells that exhibit autoreactivity to CD1d and provide a molecular basis for how a gammadelta TCR binds CD1d-alpha-galactosylceramide (alpha-GalCer). alpha-galactosylceramide 166-190 CD1d molecule Homo sapiens 95-99 24498010-1 2014 Many analogues of the glycolipid alpha-galactosylceramide (alpha-GalCer) are known to activate iNKT cells through their interaction with CD1d-expressing antigen-presenting cells, inducing the release of Th1 and Th2 cytokines. alpha-galactosylceramide 33-57 CD1d molecule Homo sapiens 137-141 24498010-1 2014 Many analogues of the glycolipid alpha-galactosylceramide (alpha-GalCer) are known to activate iNKT cells through their interaction with CD1d-expressing antigen-presenting cells, inducing the release of Th1 and Th2 cytokines. alpha-galactosylceramide 59-71 CD1d molecule Homo sapiens 137-141 25796193-1 2015 CD1d-restricted invariant natural killer T (iNKT) cells constitute an important immunoregulatory T cell subset that can be activated by the synthetic glycolipid alpha-galactosylceramide (alpha-GalCer) and initiate antitumor immune responses. alpha-galactosylceramide 161-185 CD1d molecule Homo sapiens 0-4 25796193-1 2015 CD1d-restricted invariant natural killer T (iNKT) cells constitute an important immunoregulatory T cell subset that can be activated by the synthetic glycolipid alpha-galactosylceramide (alpha-GalCer) and initiate antitumor immune responses. alpha-galactosylceramide 187-199 CD1d molecule Homo sapiens 0-4 25452463-4 2014 Similar to type I natural killer T (NKT) cells, CD1d-lipid Ag-reactive delta/alphabeta T cells recognized alpha-galactosylceramide (alpha-GalCer); however, their fine specificity for other lipid Ags presented by CD1d, such as alpha-glucosylceramide, was distinct from type I NKT cells. alpha-galactosylceramide 106-130 CD1d molecule Homo sapiens 48-52 25452463-4 2014 Similar to type I natural killer T (NKT) cells, CD1d-lipid Ag-reactive delta/alphabeta T cells recognized alpha-galactosylceramide (alpha-GalCer); however, their fine specificity for other lipid Ags presented by CD1d, such as alpha-glucosylceramide, was distinct from type I NKT cells. alpha-galactosylceramide 132-144 CD1d molecule Homo sapiens 48-52 23239102-4 2014 Although a number of glycolipid antigens have been shown to complex with CD1d molecules, most notably the marine sponge derived glycolipid alpha-galactosylceramide (alpha-GalCer), there has been debate as to the identity of the endogenous activating lipid presented to the T-cell receptor (TCR) via the CD1d molecule on antigen-presenting cells (APCs). alpha-galactosylceramide 139-163 CD1d molecule Homo sapiens 73-77 23239102-4 2014 Although a number of glycolipid antigens have been shown to complex with CD1d molecules, most notably the marine sponge derived glycolipid alpha-galactosylceramide (alpha-GalCer), there has been debate as to the identity of the endogenous activating lipid presented to the T-cell receptor (TCR) via the CD1d molecule on antigen-presenting cells (APCs). alpha-galactosylceramide 139-163 CD1d molecule Homo sapiens 73-86 24619678-3 2014 Here, we provide a detailed methodology for the generation of (CD1d-expressing) monocyte-derived DC (moDC) and their subsequent loading with the iNKT cell agonist alpha-galactosylceramide (alpha-GalCer) or their direct ligation by agonistic anti-CD1d monoclonal antibodies. alpha-galactosylceramide 163-187 CD1d molecule Homo sapiens 63-67 24619678-3 2014 Here, we provide a detailed methodology for the generation of (CD1d-expressing) monocyte-derived DC (moDC) and their subsequent loading with the iNKT cell agonist alpha-galactosylceramide (alpha-GalCer) or their direct ligation by agonistic anti-CD1d monoclonal antibodies. alpha-galactosylceramide 163-187 CD1d molecule Homo sapiens 246-250 24076636-3 2013 We describe a population of human Vdelta1(+) gammadelta T cells that exhibit autoreactivity to CD1d and provide a molecular basis for how a gammadelta TCR binds CD1d-alpha-galactosylceramide (alpha-GalCer). alpha-galactosylceramide 166-190 CD1d molecule Homo sapiens 161-165 23615906-5 2013 At least some of these CD1d-beta2m heterodimers are shorter-lived and can be rescued by provision of a defined exogenous antigen, alpha-galactosylceramide. alpha-galactosylceramide 130-154 CD1d molecule Homo sapiens 23-27 23885215-4 2013 We demonstrate here that CD1c, which is co-expressed with CD1d on blood dendritic cells and on a fraction of B cells, is able to present alpha-galactosylceramide (alpha-GalCer) as a weak agonist to human iNKT cells, and that the presence of CD1c synergistically enhances alpha-GalCerdependent activation of iNKT cells by CD1d. alpha-galactosylceramide 137-161 CD1d molecule Homo sapiens 58-62 23885215-4 2013 We demonstrate here that CD1c, which is co-expressed with CD1d on blood dendritic cells and on a fraction of B cells, is able to present alpha-galactosylceramide (alpha-GalCer) as a weak agonist to human iNKT cells, and that the presence of CD1c synergistically enhances alpha-GalCerdependent activation of iNKT cells by CD1d. alpha-galactosylceramide 137-161 CD1d molecule Homo sapiens 321-325 23065503-1 2013 Invariant natural killer T cells recognize glycolipid antigens such as alpha-galactosylceramide presented by CD1d. alpha-galactosylceramide 71-95 CD1d molecule Homo sapiens 109-113 23518808-3 2013 Type I NKT cells have an invariant T-cell receptor alpha-chain and are readily detectable by alpha-galactosylceramide (alpha-GalCer)-loaded CD1d tetramers. alpha-galactosylceramide 93-117 CD1d molecule Homo sapiens 140-144 23518808-3 2013 Type I NKT cells have an invariant T-cell receptor alpha-chain and are readily detectable by alpha-galactosylceramide (alpha-GalCer)-loaded CD1d tetramers. alpha-galactosylceramide 119-131 CD1d molecule Homo sapiens 140-144 23458425-3 2013 The prototypical CD1d agonist, alpha-galactosyl ceramide (alpha-GalCer) 1, instigates a powerful immune response and the generation of a wide range of cytokines when it is presented to iNKT cell TCRs by CD1d molecules. alpha-galactosylceramide 31-56 CD1d molecule Homo sapiens 17-21 23458425-3 2013 The prototypical CD1d agonist, alpha-galactosyl ceramide (alpha-GalCer) 1, instigates a powerful immune response and the generation of a wide range of cytokines when it is presented to iNKT cell TCRs by CD1d molecules. alpha-galactosylceramide 31-56 CD1d molecule Homo sapiens 203-207 23458425-3 2013 The prototypical CD1d agonist, alpha-galactosyl ceramide (alpha-GalCer) 1, instigates a powerful immune response and the generation of a wide range of cytokines when it is presented to iNKT cell TCRs by CD1d molecules. alpha-galactosylceramide 58-70 CD1d molecule Homo sapiens 17-21 23458425-3 2013 The prototypical CD1d agonist, alpha-galactosyl ceramide (alpha-GalCer) 1, instigates a powerful immune response and the generation of a wide range of cytokines when it is presented to iNKT cell TCRs by CD1d molecules. alpha-galactosylceramide 58-70 CD1d molecule Homo sapiens 203-207 22968995-2 2013 Upon stimulation with the CD1d-presented synthetic antigen alpha-galactosylceramide, human and rodent type I invariant NKT cells release large amounts of cytokines. alpha-galactosylceramide 59-83 CD1d molecule Homo sapiens 26-30 22445102-0 2012 Towards multivalent CD1d ligands: synthesis and biological activity of homodimeric alpha-galactosyl ceramide analogues. alpha-galactosylceramide 83-108 CD1d molecule Homo sapiens 20-24 22683545-4 2012 Measuring ex vivo activation of NKT cells by the CD1d-restricted glycolipid ligand alpha-Galactosylceramide (alpha-GalCer) through cytokine expression profiles is a useful marker of NKT cell function, but for reasons that are unclear, this approach does not appear to work as well in humans and non-human primate macaque models in comparison to mice. alpha-galactosylceramide 83-107 CD1d molecule Homo sapiens 49-53 22445102-1 2012 A library of dimeric CD1d ligands, containing two alpha-galactosyl ceramide (alpha-GalCer) units linked by spacers of varying lengths has been synthesised. alpha-galactosylceramide 50-75 CD1d molecule Homo sapiens 21-25 22445102-1 2012 A library of dimeric CD1d ligands, containing two alpha-galactosyl ceramide (alpha-GalCer) units linked by spacers of varying lengths has been synthesised. alpha-galactosylceramide 77-89 CD1d molecule Homo sapiens 21-25 22652050-0 2012 New CD1d agonists: synthesis and biological activity of 6""-triazole-substituted alpha-galactosyl ceramides. alpha-galactosylceramide 81-107 CD1d molecule Homo sapiens 4-8 22639457-1 2012 The immunomodulatory glycolipid alpha-galactosylceramide (alpha-GalCer) binds to CD1d and exhibits potent activity as a ligand for invariant CD1d-restricted natural killer-like T cells (iNKT cells). alpha-galactosylceramide 32-56 CD1d molecule Homo sapiens 81-85 22639457-1 2012 The immunomodulatory glycolipid alpha-galactosylceramide (alpha-GalCer) binds to CD1d and exhibits potent activity as a ligand for invariant CD1d-restricted natural killer-like T cells (iNKT cells). alpha-galactosylceramide 32-56 CD1d molecule Homo sapiens 141-145 22639457-1 2012 The immunomodulatory glycolipid alpha-galactosylceramide (alpha-GalCer) binds to CD1d and exhibits potent activity as a ligand for invariant CD1d-restricted natural killer-like T cells (iNKT cells). alpha-galactosylceramide 58-70 CD1d molecule Homo sapiens 81-85 22639457-1 2012 The immunomodulatory glycolipid alpha-galactosylceramide (alpha-GalCer) binds to CD1d and exhibits potent activity as a ligand for invariant CD1d-restricted natural killer-like T cells (iNKT cells). alpha-galactosylceramide 58-70 CD1d molecule Homo sapiens 141-145 22407918-4 2012 Using a baculoviral vector carrying the CD1d gene, we produced CD1d-overexpressing hESC-DCs and demonstrated that the upregulated CD1d was functional in presenting alpha-galactosylceramide for iNKT cell expansion. alpha-galactosylceramide 164-188 CD1d molecule Homo sapiens 40-44 22407918-4 2012 Using a baculoviral vector carrying the CD1d gene, we produced CD1d-overexpressing hESC-DCs and demonstrated that the upregulated CD1d was functional in presenting alpha-galactosylceramide for iNKT cell expansion. alpha-galactosylceramide 164-188 CD1d molecule Homo sapiens 63-67 22407918-4 2012 Using a baculoviral vector carrying the CD1d gene, we produced CD1d-overexpressing hESC-DCs and demonstrated that the upregulated CD1d was functional in presenting alpha-galactosylceramide for iNKT cell expansion. alpha-galactosylceramide 164-188 CD1d molecule Homo sapiens 63-67 22407918-5 2012 Pulsed with melanoma Ag recognized by T cell 1 peptide, the CD1d-overexpressing hESC-DCs displayed enhanced capability to prime CD8(+) T cells without relying on alpha-galactosylceramide loading. alpha-galactosylceramide 162-186 CD1d molecule Homo sapiens 60-64 21169066-5 2011 iNKT specifically recognize the glycolipid alpha-galactosylceramide in the context of CD1d resulting in their activation. alpha-galactosylceramide 43-67 CD1d molecule Homo sapiens 86-90 23109910-4 2012 Here we present crystallographic and biophysical analyses of alpha-galactosylceramide (alpha-GalCer) recognition by a human CD1d-restricted TCR that utilizes a Valpha3.1-Jalpha18 rearrangement and displays a more restricted specificity for alpha-linked glycolipids than that of iNKT TCRs. alpha-galactosylceramide 61-85 CD1d molecule Homo sapiens 124-128 23109910-4 2012 Here we present crystallographic and biophysical analyses of alpha-galactosylceramide (alpha-GalCer) recognition by a human CD1d-restricted TCR that utilizes a Valpha3.1-Jalpha18 rearrangement and displays a more restricted specificity for alpha-linked glycolipids than that of iNKT TCRs. alpha-galactosylceramide 87-99 CD1d molecule Homo sapiens 124-128 24900444-0 2012 Heteroaromatic Moieties in the Sphingosine Backbone of alpha-Galactosylceramides for Noncovalent Interactions with CD1d. alpha-galactosylceramide 55-80 CD1d molecule Homo sapiens 115-119 21653690-2 2011 Activation of NKT cells is crucial for their antitumor activity and is induced by alpha-galactosylceramide (alpha-GalCer, KRN7000) presented by CD1d on dendritic cells (DC). alpha-galactosylceramide 82-106 CD1d molecule Homo sapiens 144-148 21394364-1 2011 Associated with the CD1d protein, KRN 7000, a potent synthetic alpha-galactosylceramide, is known to activate the invariant NKT immune cells. alpha-galactosylceramide 63-87 CD1d molecule Homo sapiens 20-24